Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Becton Dickinson and PEPFAR Launch “Labs for Life” to Strengthen Laboratories in Developing Regions

By LabMedica International staff writers
Posted on 27 Sep 2012
A new collaboration, valued at USD 20 Million, between global medical technology leader Becton, Dickinson and Company (BD; Franklin Lakes, NJ, USA) and the US President’s Emergency Plan for AIDS Relief (PEPFAR; Washington DC, USA) through the US Department of Health and Human Services’ Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) has now launched “Labs for Life” to help strengthen healthcare and laboratory systems in resource-limited regions heavily burdened by disease.

The new five-year program, announced at the 2012 International AIDS Conference, will continue efforts in Africa as well as increase scope to include additional regions and diseases. More...
It builds on a successful prior five-year public-private partnership (PPP) between BD and PEPFAR (the largest component of the President’s Global Health Initiative) that focused on regions severely affected by HIV/AIDS and tuberculosis (TB). Assessing the performance of this PPP, Cardno, an external auditing company, reported that countries where capacity building took place not only improved the quality of services available to local populations, but also became regional centers of excellence in Africa. “Our work with PEPFAR over the last five years has demonstrated how the private sector can effectively apply its technologies and expertise to have a positive impact on healthcare in the regions most heavily burdened by disease,” said Vincent A. Forlenza, Chairman of the Board, Chief Executive Officer and President, BD.

“The US is strengthening health systems in developing countries for the long term by supporting national leadership in creating programs that are country-owned and respond to local needs,” said Ambassador Eric Goosby, coordinator at the CDC’s Division of Global HIV/AIDS (DGHA).

“The collaboration between PEPFAR and BD exemplifies the unique impact that public-private partnerships can have on addressing health challenges in the developing world,” said Thomas Frieden, Director, CDC. The Labs for Life program will include Uganda, Kenya, Ethiopia, and Mozambique, and expand outside of Africa to India, and will primarily focus on improvement for laboratory services to attain accreditation; laboratory human resources training on pathology, forecasting, and optimization; curriculum development and training on equipment maintenance; collaboration with the African Centre for Integrated Laboratory Training (ACILT) and the African Society for Laboratory Medicine (ASLM) to strengthen local capacity and promote country ownership and sustainability; and use of HIV systems to address non-communicable diseases (such as diabetes) and creation of capabilities in health systems to adopt point-of-care technologies.

Related Links:

US President’s Emergency Plan for AIDS Relief
Becton, Dickinson and Company
CDC Division of Global HIV/AIDS (DGHA)



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hybrid Pipette
SWITCH
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.